Desoize B, Carpentier Y, Guerrier D
Institut J. Godinot, GIBSA, Reims, France.
Anticancer Res. 1989 Nov-Dec;9(6):1701-5.
B6D2F1 mice bearing 3LL were more sensitive to FAA than control mice, the LD50 being 180 x 2 and 336 x 2 mg/kg respectively. At a dosage of 140 mg/kg, injected i.p. at day 4 and 11, FAA significantly decreased the primary tumour growth, the occurrence and the growth of spontaneous pulmonary metastases. The effect of two injections was dose-dependent on the primary tumour and metastases; the survival time was also dose-related. Combined with primary tumour ablation, FAA administered before any dissemination (at day 3) was more efficient against metastases than when it was injected after the end of the dissemination (i.e. after primary tumour ablation). When all treatment schedules were pooled, the number of mice without metastasis was significantly higher in treated than in control groups. The effect of FAA on recurrences was also notable.
携带3LL肿瘤的B6D2F1小鼠比对照小鼠对FAA更敏感,其半数致死量分别为180×2和336×2mg/kg。在第4天和第11天腹腔注射140mg/kg的剂量时,FAA显著降低了原发性肿瘤的生长、自发性肺转移的发生和生长。两次注射的效果对原发性肿瘤和转移灶呈剂量依赖性;生存时间也与剂量相关。与原发性肿瘤切除相结合,在任何播散之前(第3天)给予FAA比在播散结束后(即原发性肿瘤切除后)注射对转移灶更有效。当汇总所有治疗方案时,治疗组中无转移的小鼠数量显著高于对照组。FAA对复发的影响也很显著。